Leerink Partnrs Reaffirms Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)
The Cerbat Gem -

Leerink Partnrs reiterated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research report sent to investors on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($1.34) EPS, Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.27) EPS, Q4 2024 […]

In related news

  • AtriCure (NASDAQ:ATRC) Raised to Outperform at Oppenheimer

    Oppenheimer upgraded shares of AtriCure (NASDAQ:ATRC – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Tuesday morning, Marketbeat.com reports. They currently have $32.00 target price on the medical device company’s stock. Other research analysts have also recently issued reports about the stock. Stifel Nicolaus […]

  • Beam Therapeutics (NASDAQ:BEAM) Shares Down 6.6%

    Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) dropped 6.6% on Thursday . The stock traded as low as $20.84 and last traded at $21.23. Approximately 468,916 shares were traded during trading, a decline of 67% from the average daily volume of 1,435,909 shares. The stock had previously closed at $22.74. Wall Street Analysts Forecast […]

  • Relay Therapeutics (NASDAQ:RLAY) Shares Down 7.6%

    Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report)’s stock price dropped 7.6% during mid-day trading on Thursday . The stock traded as low as $5.83 and last traded at $5.87. Approximately 127,207 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 1,136,857 shares. The stock had previously closed […]